ParkinsonCanadaV1, PascalFrancis, Checkpoint, bibRecord, 000D25

Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist

Identifieur interne : 000D25 ( PascalFrancis/Checkpoint ); précédent : 000D24; suivant : 000D26

Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist

Auteurs : M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France]

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1998.

RBID : Pascal:98-0274247

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lobe frontal syndrome, Trouble attention, Chimiothérapie, Traitement, Agoniste, Récepteur α1-adrénergique, Noradrénaline, Neurotransmetteur, Test neuropsychologique, Potentiel évoqué cognitif, Stimulus acoustique, Electrodiagnostic, Homme, Naphtoxazine.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Acoustic stimulus, Agonist, Attentional disorder, Chemotherapy, Electrodiagnosis, Event evoked potential, Frontal lobe syndrome, Human, Neuropsychological test, Neurotransmitter, Norepinephrine, Parkinson disease, Treatment, α1-Adrenergic receptor.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000E20
to stream PascalFrancis, to step Curation: 001103

Links to Exploration step

Pascal:98-0274247

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α<sub>1</sub>
 agonist</title>
<author><name sortKey="Bedard, M A" sort="Bedard, M A" uniqKey="Bedard M" first="M.-A." last="Bedard">M.-A. Bedard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHUM, Notre Dame Pavillon, and UQAM</s1>
<s2>Montréal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="El Massioui, F" sort="El Massioui, F" uniqKey="El Massioui F" first="F." last="El Massioui">F. El Massioui</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>CNRS-URA 654, Salpêtrière Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malapani, C" sort="Malapani, C" uniqKey="Malapani C" first="C." last="Malapani">C. Malapani</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B." last="Pillon">B. Pillon</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Renault, B" sort="Renault, B" uniqKey="Renault B" first="B." last="Renault">B. Renault</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>CNRS-URA 654, Salpêtrière Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0274247</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0274247 INIST</idno>
<idno type="RBID">Pascal:98-0274247</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E20</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001103</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D25</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α<sub>1</sub>
 agonist</title>
<author><name sortKey="Bedard, M A" sort="Bedard, M A" uniqKey="Bedard M" first="M.-A." last="Bedard">M.-A. Bedard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHUM, Notre Dame Pavillon, and UQAM</s1>
<s2>Montréal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="El Massioui, F" sort="El Massioui, F" uniqKey="El Massioui F" first="F." last="El Massioui">F. El Massioui</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>CNRS-URA 654, Salpêtrière Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Malapani, C" sort="Malapani, C" uniqKey="Malapani C" first="C." last="Malapani">C. Malapani</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B." last="Pillon">B. Pillon</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Renault, B" sort="Renault, B" uniqKey="Renault B" first="B." last="Renault">B. Renault</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>CNRS-URA 654, Salpêtrière Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acoustic stimulus</term>
<term>Agonist</term>
<term>Attentional disorder</term>
<term>Chemotherapy</term>
<term>Electrodiagnosis</term>
<term>Event evoked potential</term>
<term>Frontal lobe syndrome</term>
<term>Human</term>
<term>Neuropsychological test</term>
<term>Neurotransmitter</term>
<term>Norepinephrine</term>
<term>Parkinson disease</term>
<term>Treatment</term>
<term>α1-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lobe frontal syndrome</term>
<term>Trouble attention</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Agoniste</term>
<term>Récepteur α1-adrénergique</term>
<term>Noradrénaline</term>
<term>Neurotransmetteur</term>
<term>Test neuropsychologique</term>
<term>Potentiel évoqué cognitif</term>
<term>Stimulus acoustique</term>
<term>Electrodiagnostic</term>
<term>Homme</term>
<term>Naphtoxazine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α<sub>1</sub>
 agonist</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BEDARD (M.-A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>EL MASSIOUI (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MALAPANI (C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUBOIS (B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PILLON (B.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>RENAULT (B.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA14 i1="01"><s1>CHUM, Notre Dame Pavillon, and UQAM</s1>
<s2>Montréal</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>CNRS-URA 654, Salpêtrière Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>INSERM U-289</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>108-117</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000075288480070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>53 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0274247</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lobe frontal syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Frontal lobe syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Lóbulo frontal síndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble attention</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Attentional disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno atención</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Agonist</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Agonista</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur α1-adrénergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>α1-Adrenergic receptor</s0>
<s5>07</s5>
<s6>«α1-»Adrenergic receptor</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor α1-adrenérgico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Noradrénaline</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Norepinephrine</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Noradrenalina</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Test neuropsychologique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Neuropsychological test</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Prueba neuropsichologica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Potentiel évoqué cognitif</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Event evoked potential</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Potencial evocado cognitivo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Stimulus acoustique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Acoustic stimulus</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estímulo acústico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Electrodiagnostic</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Electrodiagnosis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Electrodiagnóstico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Naphtoxazine</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>180</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Canada</li>
<li>France</li>
</country>
<region><li>Québec</li>
<li>Île-de-France</li>
</region>
<settlement><li>Montréal</li>
<li>Paris</li>
</settlement>
<orgName><li>Hôpital de la Salpêtrière</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Québec"><name sortKey="Bedard, M A" sort="Bedard, M A" uniqKey="Bedard M" first="M.-A." last="Bedard">M.-A. Bedard</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="El Massioui, F" sort="El Massioui, F" uniqKey="El Massioui F" first="F." last="El Massioui">F. El Massioui</name>
</region>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<name sortKey="Malapani, C" sort="Malapani, C" uniqKey="Malapani C" first="C." last="Malapani">C. Malapani</name>
<name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B." last="Pillon">B. Pillon</name>
<name sortKey="Renault, B" sort="Renault, B" uniqKey="Renault B" first="B." last="Renault">B. Renault</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000D25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:98-0274247
   |texte=   Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist

Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri